Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for

sports on the highest level with type 1. And it's diabetes awareness momth!

It's all coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy.

We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month.

Okay.. our top story this week:

XX

Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign.

https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs

XX

Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.

Statement from Dexcom:

We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information.

These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly.

Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time.

We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices.

XX

Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter.

Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned.

Source: Drug Delivery Business News

XX

In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications.

Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk.

Source: Medscape

XX

New research suggests that widely used tools for predicting heart disease risk may significantly underestimate that risk in people with type 1 diabetes. Researchers analyzed decades of data from more than 1,300 participants in the long-running DCCT/EDIC study and found that actual cardiovascular events occurred more frequently than several standard risk calculators predicted. Adding a coronary artery calcium scan, which looks for calcium buildup in the arteries, improved predictions somewhat, but not dramatically. The findings, presented at the 2026 European Association for the Study of Diabetes meeting, highlight the need for better heart disease risk assessment tools designed specifically for people with type 1.

Source: Medscape

XX

Eli Lilly is reporting impressive results for retatrutide, its experimental drug that targets three different hormone receptors, including GLP-1. In a Phase 3 study involving nearly 1,300 adults with type 2 diabetes, retatrutide lowered A1C by 2.2 percentage points, compared with 1.8 points for Ozempic. Participants taking retatrutide also lost an average of 44 to 47 pounds, roughly twice as much as those taking Ozempic. Side effects, including diarrhea and unusual skin sensations, were more common with retatrutide. The drug is not yet approved, and Lilly plans to seek FDA approval in early 2027.

Source: BioSpace

XX

It's official: MiniMed is now a fully independent company, completing its separation from longtime parent company Medtronic. MiniMed went public earlier this year, and Medtronic has now exchanged its remaining shares, ending its ownership stake in the diabetes technology business. MiniMed CEO Que Dallara says the independence gives the company more freedom to make decisions and advance diabetes care. The company is still working to separate some of its technology services from Medtronic, a process expected to continue into 2027.

Source: MedTech Dive

XX

Still to come, an implant designed to remove excess glucose without medication, help for younger adults with type 2, and type 1 hits the streets of new York.. right after this.

XX

Scientists in Switzerland and France have developed an experimental implant that removes excess glucose from the blood without using insulin or other diabetes medications. The tiny wireless device works with a continuous glucose monitor and uses an electrical reaction to convert glucose into a substance called gluconate, which is then cleared by the kidneys. In mice with type 2 diabetes and obesity, the device lowered blood sugar and reduced body weight by about 10% over six weeks. Researchers say the technology could eventually offer a new approach to treating type 2 diabetes, but it's still in the very early stages, with no human trials yet.

Source: Live Science

XX

A new study suggests that an intensive diet and exercise program can help some younger adults with type 2 diabetes achieve remission in just six months. Researchers followed 96 adults under age 45 and found that 54% of those in a medically supervised program achieved remission, compared with just 4% receiving standard care. The program included a very low-calorie diet of 800 to 900 calories per day during its initial phase, along with structured aerobic and strength training. Remission means blood sugar returns below the diabetes threshold without glucose-lowering medication, but it doesn't necessarily mean a permanent cure. These findings apply to type 2 diabetes, not type 1, and the intensive program was conducted under medical supervision.

Source: ScienceDaily

XX

Two big shoutouts for type 1 diabetes and sports. Major congrats to everyone who completed or even attempted the NYC Marathon – I'm in awe of how much training you've all put in. What an amazing accomplishment. And of course, I know some time has gone by, but one more mention of Garrett Mitchell from the World Series champion Milwakee Brewers.

A big week for people with type 1 diabetes in sports! Congratulations to everyone with T1D who took on the New York City Marathon, and a special shoutout to Milwaukee Brewers outfielder Garrett Mitchell. We'll have more on Mitchell and his story coming up.

XX

I anticipate a lot of diabetes month news and campaigns and I'll share on social if I find them interesting and actionable. I don't really do much that's different – every month is diabetes awareness month around here. I do think it's a wonderful time to get information out to the non-diabetes community. Project Blue Novmeber always does a great job all month long if you're looking to shrae iformatoin via social.

That's it for in the news!

This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. Plus, it's diabetes awareness month!

Our Community Commercial is for The Accessible Insulin Pump Task Force

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

Episode transcript:

What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes.

I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care.

We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it.

This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

More about the Congress here

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this bonus episode of diabetes connections.. the creator of Gluki, a new app designed to help kids understand diabetes through games, rewards, and interactive learning.

I'm talking to Staci DePatie who lives with type 1. Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it's as part of a game.

This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series!

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://www.diabetes-connections.comhttps://diabetes-connections.com/

Transcript:

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up.

Off to Seattle in a couple of days for MNO..

Okay.. our top story this week:

XX

Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.

The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms.

The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features.

Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here..

(clip)

I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration.

I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update.

XX

Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.

XX

SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective.

https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html

XX

Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes.

https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe

XX

A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1

diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10

XX

A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy.

T1d pregnancy and me study team, we did an episode on this.

XX

A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary.

https://www.sciencedaily.com/releases/2026/10/261017230031.htm

XX

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).

From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.

"Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shaping new treatments, and what people need from care today," said Dr Thomas Danne, Chief Medical Officer, International for Breakthrough T1D. "The most valuable discussions were the ones that connected those questions. That is how we make research more useful to the clinicians and communities it is meant to serve."

During CRC 2026, attendees explored the latest scientific and clinical advances during more than 80 sessions covering critical focus areas such as endocrinology, discovery science and immunotherapies, emerging technologies like AI and digital twins, islet cell and disease-modifying therapies, and access to care for the T1D community. Key moments from the two and half days of programming can be found in daily recaps below:

• CRC 2026 Recap: Day 1
• CRC 2026 Recap: Day 2
• CRC 2026 Recap: Day 3

We'll have more on this in an episode next week.

https://www.prnewswire.com/news-releases/breakthrough-t1d-concludes-inaugural-clinical--research-congress-highlighting-global-advances-in-type-1-diabetes-research-302906186.html

XX

Up next, Dexcom for type 2 and in athletes with T1D, technology news from omnipod and ascensia, and T1D takes the spotlight in the big leagues of baseball.. right after this.

XX

Ascensia Diabetes Care teams up with Sava Technologies to support the introduction and future commercialization of its wearable microsensor, currently under development. The technology is being designed to continuously monitor relevant biomarkers and molecules, starting with glucose, just beneath the skin.

Sava is planning for a pivotal clinical study for its CGM technology this year and aims to obtain CE approval and launch the microsensor within the next 18 to 24 months. Ascensia makes the CONTOUR® portfolio of blood glucose monitoring systems. They were partnered with Senseonics, the makers of the Eversense 365 implantable CGM but spun that business off last year

https://www.businesswire.com/news/home/20261008725757/en/Ascensia-Announces-Strategic-Partnership-with-Sava-for-Innovative-Microsensor-Technology

XX

Insulet Corporation announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs).

With Omnipod Discover, Omnipod 5 users get simple, personalized glucose and insulin delivery reports sent directly to their smartphone weekly, so they know where to focus their diabetes management efforts. Omnipod Discover also helps HCPs make confident clinical recommendations from a concise report by overlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events.

In June, Insulet presented Real-World Glycemic Outcomes1 using the Omnipod Discover platform at the American Diabetes Association's Scientific Sessions in New Orleans, Louisiana. Use of Omnipod Discover was associated with improvements in time in range (TIR), with 32% of users seeing a clinically meaningful increase in TIR of 3% or more. These findings support the vital role that user engagement with Omnipod Discover can play in diabetes self-management.

https://investors.insulet.com/news/news-details/2026/Insulet-Announces-Omnipod-Discover-Now-Available-in-U-S-/default.aspx

XX

We talked about this study with Dexcom in our bonus episode last week, but it's worth revisiting now that the results have been published in the New England Journal of Medicine. The Dexcom-funded study found that people with type 2 diabetes who don't use insulin saw significant improvements in blood sugar management when using a continuous glucose monitor. After 26 weeks, participants using Dexcom's G7 lowered their average A1C from 8.8% to 7.2%, compared to a drop from 8.7% to 8% for those receiving routine care. CGM users also spent about five additional hours each day in their target glucose range. The findings come as Medicare considers expanding CGM coverage to people with diabetes who don't use insulin, potentially opening access to millions more Americans. A decision on that expansion is expected before the end of the year, although the timing remains uncertain.

https://www.medtechdive.com/news/nejm-study-supports-cgm-use-for-people-with-diabetes-who-dont-take-insulin/833124/

XX

New research from Dexcom suggests that more young adults with type 1 diabetes are staying involved in sports, and feelings of isolation and stigma are declining. The percentage who quit sports after diagnosis dropped from 24% in 2022 to 16% in 2026, while those reporting frequent loneliness fell from 28% to 15%. But challenges remain, with fear of low blood sugar and the complexity of managing diabetes during exercise among the biggest reasons people stop playing. The research also found that young adults who started using a CGM within a year of diagnosis reported fewer glucose management challenges and less fear of lows than those who started later. The findings come as Dexcom launches its fifth season of Dexcom U, featuring 27 college athletes with diabetes across 13 sports. The program aims to increase visibility and show young people with T1D what's possible.

XX

Dexcom has announced a new partnership with Team Novo Nordisk, the world's only professional cycling team made up entirely of athletes with diabetes. Dexcom will become the team's official continuous glucose monitoring partner, with plans to support research, education, and awareness about managing type 1 diabetes during demanding physical activity. Team co-founder Phil Southerland says seeing professional athletes using the same diabetes technology as kids at home can make a powerful difference. Cyclist David Lozano, who's been with the team since 2012, says CGM technology has transformed how he trains, allowing him to see where his glucose is heading rather than just where it's been. The partnership also aims to highlight the role of diabetes technology in helping people with T1D pursue their athletic goals.

XX

A powerful moment in Major League Baseball this week as Milwaukee Brewers outfielder Garrett Mitchell, who was diagnosed with type 1 diabetes at age 9, hit the game-winning home run that sent his team to the World Series. Mitchell has faced doubts throughout his career about whether he could stay healthy enough to handle a full baseball season, but this year he's played more games than in his previous four seasons combined. His father, Antony, says Garrett has always been motivated to prove people wrong, and that managing diabetes behind the scenes takes tremendous work. Mitchell uses an insulin pump and monitors his glucose throughout games, and he's also become a role model for young athletes with T1D. His dad summed up the emotional moment this way: "He has managed himself for many years, and here he is, an example to kids that anything is possible." And now, after helping the Brewers complete a remarkable comeback against the Dodgers, Mitchell is headed to the World Series.

https://www.mlb.com/news/garrett-mitchell-hits-go-ahead-homer-to-send-brewers-to-world-series

A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.

So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?

I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 - and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.

Our past episodes with Sernova here

This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD international conference. I'm asking your questions about longer sensor wear for kids, changes to adhesive, what's going on with the G8 and more.

Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin.

This podcast is not meant at medical advice, if you have those types of questions, please ask your healthcare provider.

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

This week on Diabetes Connections In the News…

A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.

Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.

And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://www.diabetes-connections.comhttps://diabetes-connections.com/

This week on Diabetes Connections In the News…

A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.

Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.

And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.

All that and more, coming up! It's all coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

Super excited to tell you that we have joined the Health Podcast Library! Over the years, I've been asked to join a lot of networks – and I've thought about starting my own – but this is the first one that made sense to me. Health Podcast Library is a free place to find health podcasts from credible people and organizations. The creators and organizations producing each show are reviewed before it is listed. They believe sourcing matters. They don't pay me to be there and I'm proud to say I'm the first Diabetes Show featured on the Library to sign their The Health Content Integrity Pledge is a commitment from creators across all health topics and platforms to continuously work toward embedding evidence-based principles in their content creation and platform management. As creators of health-related content, we recognize our responsibility to provide accurate, transparent, and credible information that helps people make informed decisions about their health and well-being.

Go check it out and if you're a health podcaster, consider joining.

https://healthpodcastlibrary.com/

Health podcast networks

Okay.. our top story this week:

XX

Eli Lilly says an experimental drug combination helped people with obesity or overweight and type 2 diabetes lose an average of 23.3% of their body weight over 48 weeks, while also improving A1C. The treatment, called eloraTZP, combines the experimental drug eloralintide with Lilly's approved diabetes and weight-loss medication Zepbound. At the highest dose, participants lost an average of 54.1 pounds. The results are notable because people with type 2 diabetes typically lose less weight with obesity medications than people without diabetes.

The study included 367 adults with type 2 diabetes and obesity or overweight. The combination targets three hormones involved in blood sugar, digestion and appetite: GIP, GLP-1 and amylin. Side effects, mainly gastrointestinal, were more common with the combination, and as many as 27% of participants taking eloraTZP stopped treatment. Lilly plans to begin phase 3 trials later this year.

https://www.fiercebiotech.com/biotech/lilly-raises-weight-loss-bar-its-amylin-zepbound-combo

XX

New research suggests that for people with type 1 or type 2 diabetes, keeping glucose as steady as possible may not always translate into a better quality of life. In a study of 400 people with diabetes, researchers found that spending more time in the normal glucose range was associated with better quality of life the following day. Surprisingly, greater glucose variability was also linked to better next-day well-being, as long as glucose remained within safe limits.

The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan, do not suggest that high or low blood sugar is beneficial. Instead, researchers say they may point to a tradeoff in diabetes management: the effort and restrictions involved in trying to eliminate every glucose fluctuation could sometimes interfere with everyday activities and enjoyment of life. The study combined continuous glucose monitor data with daily assessments of mood, energy, sleep, stress and overall well-being.

https://www.sciencedaily.com/releases/2026/09/260927225019.htm

XX

New guidance from the American Diabetes Association and European Association for the Study of Diabetes puts a major focus on correctly diagnosing type 1 diabetes in adults. The report says about 40% of people diagnosed with type 1 after age 30 are initially misdiagnosed as having type 2 diabetes. It emphasizes that type 1 can develop at any age and that adults with the condition may have overweight or obesity, so age and body size alone shouldn't be used to determine diabetes type.

The updated guidance recommends islet autoantibody testing when type 1 diabetes is suspected and, in some cases, C-peptide testing to determine how much insulin the body is still producing. It also discourages use of the term "LADA," or latent autoimmune diabetes in adults, saying these cases are better classified as type 1 diabetes. The report also includes expanded guidance on diabetes complications, cardiovascular risk, obesity, exercise, nutrition and mental and emotional health.

https://www.medscape.com/viewarticle/guidance-type-1-diabetes-management-adults-updated-2026a1001080

XX

Eli Lilly says its once-daily GLP-1 pill Foundayo, also known as orforglipron, lowered A1C and weight while demonstrating cardiovascular safety in adults with type 2 diabetes and obesity or overweight who were at increased risk for heart problems. In the study, participants taking Foundayo lowered their A1C by 1.6 percentage points and lost an average of 8.8% of their body weight, or nearly 18 pounds, after one year. Those taking long-acting insulin lowered A1C by 1 percentage point and gained an average of 1.7% of their body weight.

Foundayo was also found to be at least as safe as insulin glargine when researchers looked at major cardiovascular events, including heart attack and stroke. The study also reported improvements in blood pressure, waist circumference and cholesterol, along with a slower decline in kidney function. The results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.

https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3

XX

A large Norwegian study found that type 1 diabetes diagnoses among young children increased after the country introduced routine rotavirus vaccination in 2014. Researchers followed more than 740,000 children and found that the rate of type 1 diabetes before age 5 was 11% higher than expected based on trends before the vaccine was introduced. The findings were presented at the European Association for the Study of Diabetes annual meeting and published in Diabetologia.

Importantly, the study does not show that the rotavirus vaccine causes type 1 diabetes. When researchers compared fully vaccinated children directly with unvaccinated children, the difference in type 1 diabetes risk was not statistically significant. Researchers had been studying the vaccine because infections, including rotavirus, have been investigated as possible environmental factors affecting type 1 diabetes risk, and previous studies have produced conflicting results.

https://www.news-medical.net/news/20261001/Type-1-diabetes-incidence-rose-by-1125-after-rotavirus-vaccine-rollout-in-Norway.aspx

XX

A large study of children with type 1 diabetes found that very low- and low-carbohydrate diets were associated with better blood sugar control and lower insulin needs, without evidence of impaired growth or increased rates of severe low blood sugar or diabetic ketoacidosis. The research included more than 45,000 children ages 1 to 17 and used up to 25 years of data. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.

Children eating fewer carbohydrates also had smaller increases in BMI and A1C over time compared with those eating standard or higher-carbohydrate diets. However, researchers emphasized that this was an observational study, meaning it cannot prove that eating fewer carbohydrates caused these improvements. They say more research is needed to determine the long-term safety of these diets and how much carbohydrate may provide benefits while still supporting good nutrition and food variety.

https://medicalxpress.com/news/2026-10-carbohydrate-diets-linked-health-benefits.html

XX

A structured diet and exercise program helped about half of younger adults with type 2 diabetes achieve remission, according to research presented at the European Association for the Study of Diabetes annual meeting in Milan. The study focused on adults ages 18 to 45 with obesity and early-onset type 2 diabetes, a form of the condition associated with faster progression and earlier complications.

Participants in the program followed a low-calorie diet of 800 to 900 calories per day for 12 weeks, along with supervised aerobic and strength training, before transitioning to a weight-maintenance diet and independent exercise. At 24 weeks, researchers measured how many participants had an A1C below 6.5% without taking glucose-lowering medication for at least 12 weeks. The researchers compared those results with participants receiving usual diabetes care.

https://medicalxpress.com/news/2026-10-calorie-diet-early-onset-diabetes.html

XX

The FDA has approved Eli Lilly's Onswik, a once-weekly long-acting insulin for adults with type 2 diabetes. Instead of taking a daily basal insulin injection, people using Onswik will take one injection per week, potentially eliminating more than 300 injections a year. In studies involving more than 3,400 adults with type 2 diabetes, Onswik lowered A1C by amounts comparable to daily long-acting insulin.

Onswik is expected to become available in the U.S. in the coming months in pre-filled insulin pens. The insulin is approved for type 2 diabetes only and should not be used by people with type 1 diabetes because of an increased risk of severe low blood sugar. Onswik has already been approved in Europe, Japan and Mexico.

Onswik joins Novo's Awiqly – which I have to say are two of the more entertaining drugs names we've seen this year.

https://www.reuters.com/legal/litigation/us-fda-approves-lillys-once-weekly-insulin-injection-type-2-diabetes-2026-09-24/

XX

Two small studies looked at how different physical activity affects glucose levels in people with type 1 diabetes. In one, researchers tracked 110 instances of sexual activity among 12 adults using continuous glucose monitors and found no clinically significant hypoglycemia, even when sex occurred at night. Glucose sometimes rose and sometimes fell, suggesting there isn't one predictable glucose response to sexual activity.

A separate study followed 10 runners with type 1 diabetes as they completed a marathon alongside 10 runners without diabetes. All of the runners with T1D finished, with times comparable to the control group, although one runner had two low blood sugar readings. Researchers also found that CGMs became less accurate during the marathon and suggested using a glucose meter when sensor readings don't match how a runner feels. Both studies were small, but researchers say the findings could help address fear of hypoglycemia, which can affect everything from exercise to intimacy.

https://medicalxpress.com/news/2026-09-sex-safe-diabetes-small-glucose.html

http://medicalxpress.com/news/2026-09-marathons-diabetes-safe-small.html#goog_rewarded

XX

We told you about Beta Bionics iLet new compatibility with Senseonic's Eversense 365 CGM.. now the companies announce the MINT tubeless pump will also work with the year-long implantable CGM.

Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users.

The companies have also committed to the integration of mint and Eversense 365 in the future. This partnership underscores Beta Bionics' and Senseonics' shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes.

https://investors.betabionics.com/news-releases/news-release-details/beta-bionics-announces-agreement-integrate-iletr-bionic-pancreas

XX

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom.

No word yet on the tubeless Mobi – still waiting to hear from the FDA on that.

Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,* and a 200-unit cartridge.

https://www.businesswire.com/news/home/20260928831177/en/Tandem-Mobi-Automated-Insulin-Delivery-System-Now-Available-in-Twelve-International-Markets

XX

Many people with type 2 diabetes still face barriers to using continuous glucose monitors, according to a new report from Dexcom. The company surveyed about 2,500 people with type 2 diabetes and more than 800 healthcare professionals across eight countries. More than half of people with diabetes said they knew little about CGM as a management option, while healthcare professionals pointed to insurance coverage and reimbursement as major barriers to access.

Among people with type 2 diabetes already using CGM, 94% said the technology helped them manage their diabetes more independently and 91% said they used CGM data to help make treatment decisions. The report also found limited awareness of using CGM alongside GLP-1 medications: 72% of people with type 2 diabetes surveyed did not know the two could be used together. The findings were released by Dexcom ahead of the European Association for the Study of Diabetes annual meeting in Milan.

https://www.medicaldevice-network.com/news/dexcom-report-paints-mixed-picture-of-cgm-use-by-people-with-type-2-diabetes/?cf-view

XX

Dexcom is facing a handful of lawsuits, alleging the company's CGMs malfunctioned and caused severe medical emergencies in children.

The latest lawsuits involve a 7-year-old California girl and a 10-year-old Tennessee girl who were both hospitalized after their Dexcom G7 devices allegedly failed to accurately report blood glucose levels.

The legal firm behind 11 of these suits say they involved G7 and G6 CGMs with plantiffs in six states.

https://www.mddionline.com/diabetes/dexcom-faces-lawsuit-alleging-device-failures-endangered-children

XX

Frances Valentine, the fashion brand created by the late Kate Spade and her friend Elyce Arons, is dipping into the glamorous world of old Hollywood with a new Mary Tyler Moore collection that pays homage to the actress.

The limited-edition capsule features 20 pieces, including shirts, dresses, tote bags and, of course, shoes, all inspired by the Emmy-winning star's whimsical, upscale style. Prices start at $48 for a makeup clutch and go up to $498 for wool peacoats.

The lineup was co-created with the Mary Tyler Moore Vision Initiative, an organization dedicated to "preserving and restoring vision in people with diabetes," per the nonprofit's website. Twenty percent of proceeds from the collection will benefit the cause, which was particularly meaningful to Moore.

Type 1 diabetes is an autoimmune condition in which the pancreas produces little or no insulin, while Type 2 diabetes is a metabolic disorder. Other public figures who have spoken about living with Type 1 diabetes include model Lila Moss, Dancing With the Stars pro Rylee Arnold and musician Nick Jonas.

The Mary Tyler Moore Vision Initiative was established by Moore's husband, Dr. S. Robert Levine, following her death in 2017.

https://www.hollywoodreporter.com/lifestyle/shopping/mary-tyler-moore-frances-valentine-clothing-collection-2026-1236714592/

XX

The FDA has cleared a new app that uses continuous glucose monitor and insulin data to recommend insulin dose adjustments directly to adults with type 2 diabetes who take insulin by injection. The app, called MODI and developed by DreaMed Diabetes, can provide personalized recommendations without requiring a healthcare provider to review or approve each individual dose change.

MODI is designed for adults with type 2 diabetes who use long-acting insulin, either alone or with rapid-acting insulin. While automated insulin dosing technology has largely focused on people using insulin pumps, MODI brings automated dosing support to people who use injections. The goal is to help adjust insulin more frequently between healthcare visits, rather than waiting weeks or months for a provider to make changes.

Interesting name – there is a type of diabetes called MODY - Maturity-Onset Diabetes of the Young (MODY) is a rare, inherited form of diabetes caused by a single gene mutation that affects how the pancreas makes insulin.

https://dreamed.ai/press-releases/dreamed-receives-fda-clearance-for-modi/

https://diabetes-connections.com/we-treat-the-data-lifting-the-burden-of-diabetes-with-dreamed/

On this bonus episode of diabetes connections, we're talking about the Beyond Barriers Innovation Accelerator. This is a project from Beyond Type 1 which is investing in community-based organizations and entrepreneurs working to close those gaps. We'll hear about some really interesting projects from comic books for kids to apps for first responders and programs to help with cost…

And we'll zoom out: eleven years after Beyond Type 1 launched, what is the organization today—and how is it trying to make sure more people with diabetes have the opportunity not just to survive, but to thrive? What's the mission for Beyond Type 1 in 2026?

This podcast is not intended as medical advice, if you have those kinds of questions, please contact your healthcare provider.

More about the Innovation Accelerator and Beyond Type 1 here

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

Shannon Boggs' daughter Raelynn, was still doing backflips at gymnastics just days before she landed in the ICU in DKA and was diagnosed with type 1 diabetes.

Four years later, things look very different. Raelynn is starting middle school, taking on more of her own diabetes management, going to regular sleepaway camp, and even sharing her life with type 1 online — with hundreds of thousands of people following along.

Shannon and I talk about that sometimes-scary balance between independence and diabetes management, why finding community changed everything for their family, and how she thinks about sharing Raylan's diabetes, and her whole family's story, so publicly on social media.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out all of our events like Moms' Night Out and Club 1921 here.

Info about the bananas Chesapeake Bay Bridge Tunnel here Announcing Community Commercials! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this episode of Diabetes Connections In the news…

The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for a webinar September 23

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://www.diabetes-connections.comhttps://diabetes-connections.com/

Transcript:

On this episode of Diabetes Connections In the news…

The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..

It's all coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

We are off to Detroit this week for Moms' Night Out in Bloomfield Michigan. Super excited and as usual I'm getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well!

Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes.

Okay.. our top story this week:

XX

Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June.

Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott.

"Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday.

Kahn told MedPage Today that "the journal boycott is like establishing a picket line.

The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including:

Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions

Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee"

Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements

The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies.

https://www.medpagetoday.com/endocrinology/diabetes/122977

https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform

XX

A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users.

The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027

Mint is expected to launch exclusively through the pharmacy channel.

Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be

completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint.

https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457

XX

Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the "X cell," they're now exploring whether that discovery could lead to a new treatment for type 1 diabetes.

In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas's insulin-producing beta cells, while leaving the rest of the immune system intact.

The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin.

sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/

XX

A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D.

https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html

XX

Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition.

For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese

After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group.

Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it's kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show..

https://www.sciencedaily.com/releases/2026/09/260909231740.htm

XX

A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations.

https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx

XX

Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use was associated with a reduction in asthma attacks of nearly 40%.

The study was led by Professor Chloe Bloom, Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.

Exploring GLP 1 Drugs and Lung Health

Dr. Bloom said: "GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.

"We wanted to use real-world health records to investigate whether people with asthma or COPD who started GLP-1 receptor agonists had fewer acute respiratory attacks."

To investigate that question, the researchers analyzed electronic medical records from the UK. They carried out four parallel studies, each involving between 20,000 and 22,000 people who had started treatment with either a GLP-1 medication or a different type of diabetes drug known as a sulfonylurea.

The results suggested that people with airway diseases such as asthma and COPD who received GLP-1 therapies experienced fewer asthma attacks and COPD flare-ups than comparable patients who were prescribed other diabetes medications.

Semaglutide Showed the Strongest Effect

Among the GLP-1 drugs examined, semaglutide appeared to stand out, particularly for people with asthma.

Bloom explains: "The effect was strongest with semaglutide, especially in people with asthma, where use of semaglutide appears to be associated with nearly a 40% reduction in asthma attacks. Semaglutide also led to a 20% reduction in COPD flare-ups."

The findings suggest that people who already qualify for GLP-1 receptor agonists because they have obesity or type 2 diabetes could potentially receive an additional benefit for their respiratory health.

However, Bloom emphasized that the results are not enough to recommend these medications specifically as treatments for asthma or COPD.

She explains: "The findings from this study are encouraging, but they should not change treatment decisions on their own. People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance. While the findings suggest that some people taking GLP-1 receptor agonists may experience fewer respiratory attacks, this needs confirmation in clinical trials."

https://www.sciencedaily.com/releases/2026/09/260909005155.htm

XX

XX

A large study suggests women with endometriosis may have a higher risk of developing type 2 diabetes. Researchers analyzed health records from nearly 3 million women in Utah and found those diagnosed with endometriosis were 46% more likely to develop type 2 diabetes than those without the condition. The association was strongest among women who had not yet reached menopause and those without obesity, a group typically considered at lower risk for type 2 diabetes. Certain forms of endometriosis, including those found outside the pelvic area, were associated with more than twice the risk. Researchers say more study is needed, but the findings suggest endometriosis may have health effects beyond the reproductive system and could eventually help identify women who may benefit from earlier diabetes screening.

https://www.nih.gov/news-events/nih-research-matters/endometriosis-may-increase-type-2-diabetes-risk

XX

MiniMed files FDA submission for it's first patch pump, with a planned launch next summer. To be called MiniMed fit, it would have a 300-unit insulin reservoir and would accommodate up to seven days of wear time.

MiniMed also completed enrollment of a pivotal trial for a fully closed loop algorithm, which would calculate the amount of insulin a person needs throughout the day, even if they don't announce meals or count carbohydrates. Interestingly, on an investor call, the CEO acknowledged that CGMs have been their – quote – Achilles' heel for a very long time" and that their newest sensor has helped drive insulin pump growth.

https://www.medtechdive.com/news/minimed-submits-new-patch-pump-for-fda-clearance/829313/

XX

A new study based on national health registers in Denmark suggests starting statin treatment after a type 2 diabetes diagnosis could lower the risk of dementia, and it seems that the sooner patients did, the better.

The research, published in The Lancet Regional Health, is an observational study, meaning it can find statistically relevant patterns at the population level, but doesn't necessarily explain what caused those patterns.

The results, however, were interesting enough that the researchers, led by medical doctor Tummas Ternhamar of the Copenhagen University Hospital, are urging doctors to consider statin therapy when diagnosing type 2 diabetes patients.

"Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease."

https://www.sciencealert.com/statins-linked-to-lower-dementia-risk-in-massive-type-2-diabetes-study

XX

Big sports news with type 1. Alezander Zverev wins

Family was at the heart of Alexander Zverev's U.S. Open triumph on Sunday as the German saluted the members of his inner circle and paid a heartfelt tribute to his mother for refusing to let diabetes define his future.

The ​top seed beat American Ben Shelton 6-3 7-6(2) 5-7 6-2 at Flushing Meadows to finish a spectacular year at ‌the Grand Slams in which he proved his doubters wrong by going from perennial nearly man to two-time major champion.

Shortly after his victory, Zverev reserved special praise for his mother Irina, a former professional tennis player, and credited her with ensuring type 1 diabetes never limited his ambitions in life.

"When your 4-year-old son is diagnosed with diabetes and doctors in the office ​tell you that life and sports will be very limited for that child, it takes a very strong mother to ​say 'my son will be whatever he wants to be'," Zverev said.

"'If he wants to be a tennis player, ⁠he'll be a tennis player. If he wants to do something else, he'll do something else, but this illness will not define us'.

https://www.reuters.com/sports/tennis/zverev-hails-mothers-belief-after-us-open-triumph-2026-09-13/

XX

Also, shout out to Garrett Mitchell (Center field Milwaukee Brewers) lives with Type 1 Diabetes and hit a grand slam immediately after having a failed insulin pump site. He was diagnosed with T1D at the age of 9. And I have a T1d mom friend who's known him since he was a kid. Just great to see athletes talking about failed insulin sets like they're just part of everyday life.. because they are. Btw it was the first grand slam for the brewers all year.

XX

The new Netflix movie The Runner is getting a bit of a side eye from some in the diabetes community… the Gal Gadot thriller features a child with type 1 but as usual, there are some weird inaccuracies. Ginger Vieria from Diabetes nerd has a great vide on this – I'll link it up: but they're saying things like Insulin Dispenser instead of pump.. and some other weird stuff.. but I've heard such bad things about this movie I'm not sure it's worth watching just for this. Ginger's video is though!

https://www.youtube.com/shorts/o8cw_gEZj5s

This week on Diabetes Connections.. Now that Eversense 365-day has been out in the real world and is working with the twiist automated insulin delivery system, we're starting to get a much better picture of what that combination can actually do.

This week, Dr. Fran Kaufman is back with new data on Eversense 365, including some impressive results from people using it with twiist. We'll talk about what they're learning, who's using the year-long sensor, and what may be coming next.

And that next step is really interesting: a sensor with its own battery that could work even when the external transmitter is removed, and eventually, a fully implanted CGM that could send glucose data directly from under your skin to your phone or watch.

Plus, we talk about pediatric plans, additional pump integrations, and why — after 50 years in diabetes care — Fran says she's more excited about the future than ever.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Join us for a Webinar with Abbott: Expert Discussion: Navigating Continuous Ketone Monitoring and DKA With Confidence - Register Here

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

A few years ago, when we talked about screening for type 1 diabetes, it still felt a little bit like we were talking about the future. That future may be arriving faster than we realize.

Dr. Bryce Nelson is back on the show. After years as a pediatric endocrinologist, he's now working specifically in autoimmune type 1 diabetes with Sanofi. We talk about how much has changed with screening, what we're learning about who's at risk, and the big question: how close are we to screening becoming a routine part of healthcare?

And Jenny Hoffman shares what this looks like for a family living it. Her older son was diagnosed at two and a half; after years of screening her younger son, Asher, he tested positive for five autoantibodies at age six. He's still in stage one, and Jenny talks about the surprising difference between fearing a diagnosis and having the time to prepare for one.

Where is type 1 screening headed next? That's what we're talking about today.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Learn more about screening: https://www.screenfortype1.com/

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this episode of Diabetes Connections In the news…

The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more...

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://www.diabetes-connections.comhttps://diabetes-connections.com/

On this episode of Diabetes Connections In the news…

The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more..

that's coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes.

So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events.

Okay.. our top story this week:

XX

Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes.

The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide).

https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html

XX

The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes.

The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older.

Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app.

The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review.

https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/

XX

Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors.

The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar.

Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027.

Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group.

https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/

XX

A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia.

Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one.

The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty.

Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose

management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration

XX

We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis.

They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes.

It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes.

Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said.

https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575

XX

Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results.

But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths.

Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases.

https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035

XX

More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton.

XX

A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed.

Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties.

https://www.sciencedaily.com/releases/2026/08/260824065543.htm

XX

New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2

The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC).

Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050.

Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries.

https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx

XX

Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors.

"Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor,"

From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021.

Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis.

https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html

XX

We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children's Diabetes Foundation and the Barbara Davis Center for Diabetes.

Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others.

Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed.

We're taught about what to do when blood sugar goes high or low, but almost nothing about what to do when diabetes burnout, anxiety, or fear takes over. My guest – Dr. Mark Heyman says the biggest thing holding you back with type 1 diabetes may not be your blood sugar — but the stress of managing it. Mark lives with type 1 and his new book, Live Free with T1D, offers what he calls an "operating system" for the emotional side of diabetes — practical tools for handling the uncomfortable moments without letting them make your world smaller.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Link to get your FREE copy of "Live Free with T1D" here

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this episode of Diabetes Connections In the News…

A new basal insulin is available, researchers are working on a "cloak" designed to protect transplanted insulin-producing cells, Retatrutide isn't even approved and it's already the subject of lawsuits, tandem moves to pharmacy and more!

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

This week on Diabetes Connections, we're talking about the newest pump from MiniMed – the Flex looks a lot different from any pump produced by the company formerly known as Medtronic Diabetes. It has no screen it's controlled by phone.. and has a lot of other features we'll get into. I'm speaking to MiniMed's EVP, Chief Product and Technology Officer Ali Dianaty about the Flex, their upcoming patch pump, new software, a really interesting look at the testing of these algorithms. And a lot more.

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this episode of Diabetes Connections In the news…

Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D.

Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/

Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://www.diabetes-connections.comhttps://diabetes-connections.com/

Transcript:

(Stacey Track) On this episode of Diabetes Connections In the news…

Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share:

Events you're organizing: a fundraiser, walk, or local meetup

Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business

Helpful projects or resources: things you think others in our community should know about

It's your chance to share what you're doing and help others get connected!

Full instructions are on the website.

While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.

Okay.. our top story this week:

XX

I want to talk about Cookie Queens! It might not sound like a hard news story.. but

It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:

Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter"

https://www.youtube.com/watch?v=nnSQS43Eil8

Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12).

Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe.

Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet."

Cookie Queens comes out this month.

https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/

trailer:

XX

Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand.

The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details.

Sanofi said the situation is temporary and is expected to improve over the coming weeks.

The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available.

https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/

XX

The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1.

For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression.

The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far.

In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models.

https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing

XX

Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat.

The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications.

They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly.

The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.

The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display

The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring.

The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.

The device needs further validation in diverse clinical settings and across large diabetic cohorts.

https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx

XX

Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1.

An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level

The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years.

The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer.

The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays.

Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.

https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r

XX

Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.

The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.

https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/

XX

XX

Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..

XX

New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years.

These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women)

Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems.

And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2.

https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir

XX

Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life.

https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx

XX

Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year.

https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/

XX

The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program.

Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes.

The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress.

The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions.

https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/

XX

Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump.

Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year.

Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month.

https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/

XX

Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines.

In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device.

Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area.

https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply

XX

Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes.

"When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island."

She says she found an online community that's been helping.

In sharing her experience, she hoped it would alleviate the stress.

https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis

XX

Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes.

Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, .

https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact

For years, women with type 1 diabetes have been told their blood sugars might change because of hormones... but what does that actually mean? Why do insulin needs suddenly shift in your 40s and 50s? And why is so little research focused on women with type 1 as they move through perimenopause and menopause?

This week, I'm talking with Melissa Slemp. She has lived with type 1 diabetes for more than four decades and has written a new book about the intersection of diabetes, hormones, and aging. Plus, Melissa shares her own story—from being diagnosed in 1982, to finding diabetes community decades later

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Learn more about Moms' Night Out and Club 1921 here

Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this episode of Diabetes Connections In the news…

More accusations of censorship at the ADA, a setback for GLP1 medications for type 1, discussion of a federal insulin price cap, device news and mergers and and much more.

Check out our fall in-person events: https://diabetes-connections.com/events/

Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/

On this bonus episode of Diabetes Connections... we're talking about a fascinating new partnership between Omnipod and Calm – the meditation app, designed specifically for people with type 1 diabetes. Calm says it helps people sleep more, stress less and live mindful.. what does that look like for our community? I'm talking to advocate Meg Cremins, a Calm user who lives with type 1 and got to check out the collaboration, about what it sounds like, who it helps, and her thoughts on why caring for your mental health isn't really separate from diabetes care.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Join us at Moms' Night Out this fall (and check out our 2027 cities)!

Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page https://diabetes-connections.com/